These data indicate that growth hormone secretion may recover following successful reduction of prolactin levels after cabergoline therapy for a mean of 22 months (range 6-28 months) in most but not all subjects with a macroprolactinoma. It is therefore advisable that individuals with a macroprolactinoma in whom growth hormone replacement therapy is being considered undergo repeat assessment of growth hormone secretion following medical treatment.
No takes yet. Share an insight, caveat, or question.
George et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: